奥拉帕尼
医学
耐受性
肿瘤科
乳腺癌
内科学
PARP抑制剂
转移性乳腺癌
化疗
临床平衡
癌症
三阴性乳腺癌
临床试验
软膜
不利影响
聚ADP核糖聚合酶
化学
生物化学
基因
聚合酶
作者
Gaia Griguolo,Maria Vittoria Dieci,Federica Miglietta,Valentina Guarneri,Pier Franco Conte
出处
期刊:Future Oncology
[Future Medicine]
日期:2020-04-01
卷期号:16 (12): 717-732
被引量:8
标识
DOI:10.2217/fon-2019-0689
摘要
Olaparib, an oral PARP-inhibitor, has shown clinical benefit for HER2-negative advanced breast cancer patients carrying a germinal BRCA1/2 mutation. In a randomized Phase III trial, olaparib significantly prolonged progression-free survival as compared with chemotherapy of physician choice. Moreover, in the same trial, a prespecified subgroup analysis reported an overall survival benefit for patients not previously pretreated with chemotherapy for metastatic disease. This review focuses on available preclinical, pharmacokinetic and pharmacodynamic data regarding olaparib and clinical evidence of its antitumor efficacy (both as monotherapy and in combination) and tolerability in breast cancer patients. Open questions, such as use of appropriate biomarkers for patient selection and combination/sequencing with other anticancer drugs, are also addressed.
科研通智能强力驱动
Strongly Powered by AbleSci AI